Losartan Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Source (Contract Manufacturing Organizations, In-House), By Application (Hypertension, Stroke, Diabetic Nephropathy, Others), By Region and Competition, 2020-2030F

Market Overview

Global Losartan Market was valued at USD 728.50 Million in 2024 and is expected to reach USD 898.16 Million by 2030 with a CAGR of 3.75%. Losartan, an angiotensin II receptor antagonist, is widely prescribed for the treatment of high blood pressure, heart failure, and to protect the kidneys in patients with diabetes. Its established efficacy, cost-effectiveness, and favorable safety profile contribute to its widespread adoption in both developed and developing markets.

One of the primary drivers of the global losartan market is the rising incidence of lifestyle-related diseases such as obesity, diabetes, and hypertension. Aging populations and sedentary lifestyles have contributed significantly to the growing demand for antihypertensive medications. Additionally, increased awareness of preventive healthcare and the expanding use of generic drugs have further propelled market growth. Despite its growth, the market faces certain challenges. Regulatory scrutiny and recalls due to contamination issues have impacted consumer confidence in recent years. Additionally, the intense competition among generic manufacturers has led to price erosion, which may limit profitability for some companies.

Key Market Drivers

Growth in Healthcare Industry

The global healthcare industry generates annual sales exceeding USD 4 trillion. Among its most substantial and lucrative segments are pharmaceuticals and biotechnology, which collectively account for nearly USD 850 billion, and medical technology and diagnostics, contributing over USD 400 billion. The consistent expansion of the global healthcare industry serves as a key catalyst for the growth of the global Losartan market. As healthcare systems worldwide continue to evolve, there is an increasing emphasis on the prevention, diagnosis, and long-term management of chronic conditions, particularly cardiovascular diseases and hypertension two areas in which Losartan is commonly prescribed. This sustained focus has significantly amplified the demand for effective antihypertensive drugs, contributing directly to market expansion.

In 2021, global healthcare expenditure reached an unprecedented USD 9.8 trillion, representing 10.3% of the global GDP. Despite this significant investment, life expectancy has plateaued in several countries over the past decade including the United States, where annual healthcare spending exceeds USD 4 trillion. Rising healthcare expenditures, particularly in emerging economies, are facilitating broader access to essential medications. Governments and private sectors are investing heavily in healthcare infrastructure, enabling improved diagnosis and treatment of hypertension-related disorders. Consequently, the number of patients receiving regular therapy with angiotensin II receptor blockers, including Losartan, is steadily increasing.

Surge in Technological Advancements

The global Losartan market is witnessing significant momentum, largely propelled by a surge in technological advancements across the pharmaceutical and healthcare sectors. Innovations in drug formulation, manufacturing processes, and precision medicine have considerably enhanced the efficacy, safety, and accessibility of Losartan, thereby accelerating its adoption worldwide.

Recent drug delivery systems (DDS) are developed using advanced technologies to enhance the targeted delivery of therapeutics, ensuring faster systemic absorption and improved localization at the intended site of action. This approach maximizes therapeutic efficacy while reducing off-target distribution, thereby playing a critical role in effective disease management and treatment outcomes. Technologies such as sustained-release formulations and nanoparticle-based drug carriers are improving the pharmacokinetics of Losartan, allowing for more controlled drug release and improved patient compliance. These innovations are particularly crucial in chronic disease management, where long-term therapy and adherence are essential.

Download Free Sample Report

Key Market Challenges

Disruption in Supply Chain

One of the key challenges impacting the global losartan market is the persistent disruption in the pharmaceutical supply chain. As a widely used generic antihypertensive drug, losartan relies on a stable and consistent flow of active pharmaceutical ingredients (APIs), excipients, packaging materials, and distribution networks. However, global supply chain vulnerabilities have significantly affected the timely production and availability of losartan across several regions.

The supply chain disruptions have been driven by multiple interrelated factors. Firstly, the concentration of API manufacturing in a few countries, particularly China and India, has made the supply of raw materials highly susceptible to geopolitical tensions, export restrictions, and environmental regulations. Any interruption in API production whether due to factory shutdowns, raw material shortages, or regulatory non-compliance can cause delays in the formulation and distribution of the finished product.

Key Market Trends

Increasing Research into Combination Therapies

The growing focus on combination therapies represents a significant trend shaping the trajectory of the global Losartan market. As the complexity of managing hypertension and related cardiovascular disorders continues to rise, researchers and pharmaceutical companies are increasingly investigating the synergistic potential of Losartan when used alongside other antihypertensive agents. Combination therapies have become a cornerstone of contemporary cancer treatment, underpinned by extensive clinical trial data demonstrating superior patient outcomes with multi-drug regimens compared to monotherapies. These combinations are typically developed based on a strong biological rationale, wherein agents targeting identical or complementary molecular pathways are expected to work synergistically to improve therapeutic efficacy. This trend is driven by the need to enhance therapeutic efficacy, improve patient compliance, and achieve better long-term clinical outcomes.

Combination therapies that pair Losartan with diuretics, calcium channel blockers, or beta-blockers are gaining traction due to their ability to target multiple physiological pathways simultaneously. For instance, fixed-dose combinations of Losartan with hydrochlorothiazide have demonstrated improved blood pressure control with a reduced pill burden, thereby fostering better adherence among patients with chronic hypertension. This clinical advantage is prompting increased investment in the development of novel fixed-dose regimens involving Losartan.

Segmental Insights

Source Insights

Based on Source, Contract Manufacturing Organizations have emerged as the fastest growing segment in the Global Losartan Market in 2024. This is driven by the increasing demand for cost-efficiency, scalability, and specialized expertise in pharmaceutical production. As pharmaceutical companies face rising pressure to optimize operations, reduce overheads, and accelerate time-to-market, outsourcing to CMOs has become a strategic imperative. One of the key factors fueling this growth is the cost advantage CMOs offer. By leveraging economies of scale, advanced infrastructure, and efficient production capabilities, CMOs help pharmaceutical firms significantly lower their manufacturing expenditures.

Application Insights

Based on Application, Stroke have emerged as the fastest growing segment in the Global Losartan Market during the forecast period. This is due to a combination of increasing prevalence, heightened clinical awareness, and the drug’s proven therapeutic benefits in post-stroke management. As the global burden of stroke continues to rise driven by aging populations, sedentary lifestyles, and the growing incidence of hypertension there has been a corresponding increase in demand for effective antihypertensive agents such as losartan to mitigate post-stroke complications and reduce recurrence risk.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Losartan Market in 2024. This is due to a combination of robust healthcare infrastructure, high disease prevalence, and strong regulatory frameworks. One of the primary factors contributing to this dominance is the high incidence of hypertension and cardiovascular diseases in the region. According to data from the CDC, nearly half of adults in the United States suffer from high blood pressure, creating substantial demand for antihypertensive medications such as Losartan. This widespread prevalence ensures a consistent and growing patient base for pharmaceutical companies operating in the market.

Recent Development

• In April 2025, Scienture Holdings announced the completion of manufacturing and supply chain preparations for Arbli, its FDA-approved oral liquid losartan suspension (10mg/mL). Through its subsidiary, the company has entered into a manufacturing partnership with Saptalis Pharmaceuticals and finalized warehousing and distribution agreements. Arbli is the first and only FDA-approved ready-to-use oral liquid formulation of losartan available in the U.S. market. It is indicated for the treatment of hypertension in patients aged six years and older, for reducing the risk of stroke in hypertensive patients with left ventricular hypertrophy, and for managing diabetic nephropathy in individuals with type 2 diabetes. The product is protected by two USPTO patents pending listing in the FDA Orange Book.
• In March 2024, the Union Minister for Chemicals & Fertilizers and Health & Family Welfare formally inaugurated a series of strategic infrastructure projects aimed at strengthening India’s pharmaceutical and medical device manufacturing capabilities. This included the launch of 27 Greenfield Bulk Drug Park projects, featuring dedicated production facilities for key active pharmaceutical ingredients (APIs), including losartan. Additionally, 13 new Greenfield Manufacturing Plants for medical devices were inaugurated under the Production-Linked Incentive (PLI) Scheme, further reinforcing the government’s commitment to enhancing domestic manufacturing, reducing import dependency, and promoting self-reliance in the healthcare sector.

Key Market Players

• Merck & Co. Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Novartis International AG
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceuticals Industries Ltd.
• Aurobindo Pharma Ltd.
• Torrent Pharmaceutical Ltd.
• Lupin Ltd.

Report Scope

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Losartan Market, By Source:

o   Contract Manufacturing Organizations

o   In-House

• Losartan Market, By Application:

o   Hypertension

o   Stroke

o   Diabetic Nephropathy

o   Others

• Losartan Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Losartan Market.

Available Customizations:

Global Losartan Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Losartan Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]